Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) - Equities research analysts at Zacks Research raised their FY2025 earnings per share estimates for Prestige Consumer Healthcare in a report released on Wednesday, February 26th. Zacks Research analyst R. Department now anticipates that the company will earn $4.58 per share for the year, up from their prior estimate of $4.51. The consensus estimate for Prestige Consumer Healthcare's current full-year earnings is $4.50 per share. Zacks Research also issued estimates for Prestige Consumer Healthcare's Q4 2025 earnings at $1.29 EPS, Q1 2026 earnings at $0.99 EPS, Q2 2026 earnings at $1.17 EPS, Q4 2026 earnings at $1.36 EPS, FY2026 earnings at $4.76 EPS, Q1 2027 earnings at $1.09 EPS and FY2027 earnings at $5.03 EPS.
A number of other equities analysts also recently weighed in on PBH. StockNews.com raised Prestige Consumer Healthcare from a "hold" rating to a "buy" rating in a research report on Friday, January 24th. Sidoti lowered shares of Prestige Consumer Healthcare from a "buy" rating to a "neutral" rating and set a $90.00 price target on the stock. in a research note on Monday, December 9th. Oppenheimer raised their price objective on Prestige Consumer Healthcare from $87.00 to $93.00 and gave the company an "outperform" rating in a report on Thursday, February 13th. Canaccord Genuity Group upped their target price on Prestige Consumer Healthcare from $93.00 to $100.00 and gave the stock a "buy" rating in a report on Friday, February 7th. Finally, Raymond James raised Prestige Consumer Healthcare to a "moderate buy" rating in a research report on Thursday, December 19th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, Prestige Consumer Healthcare has an average rating of "Moderate Buy" and a consensus target price of $92.60.
Check Out Our Latest Research Report on PBH
Prestige Consumer Healthcare Trading Down 1.0 %
Shares of NYSE PBH traded down $0.86 during mid-day trading on Friday, hitting $84.39. The company's stock had a trading volume of 369,725 shares, compared to its average volume of 318,757. The company's fifty day simple moving average is $80.18 and its 200-day simple moving average is $77.40. The stock has a market cap of $4.18 billion, a price-to-earnings ratio of 19.76, a price-to-earnings-growth ratio of 2.69 and a beta of 0.50. Prestige Consumer Healthcare has a one year low of $62.35 and a one year high of $88.36. The company has a debt-to-equity ratio of 0.56, a current ratio of 3.68 and a quick ratio of 2.20.
Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last issued its earnings results on Thursday, February 6th. The company reported $1.22 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.18 by $0.04. Prestige Consumer Healthcare had a return on equity of 12.36% and a net margin of 19.13%.
Institutional Trading of Prestige Consumer Healthcare
Hedge funds have recently bought and sold shares of the business. Allspring Global Investments Holdings LLC lifted its position in shares of Prestige Consumer Healthcare by 3.1% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,624,501 shares of the company's stock worth $126,274,000 after acquiring an additional 49,331 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Prestige Consumer Healthcare by 1.7% during the fourth quarter. Geode Capital Management LLC now owns 1,348,745 shares of the company's stock valued at $105,342,000 after buying an additional 21,951 shares during the last quarter. Kayne Anderson Rudnick Investment Management LLC bought a new stake in Prestige Consumer Healthcare in the fourth quarter valued at approximately $84,932,000. Invesco Ltd. increased its stake in shares of Prestige Consumer Healthcare by 2.4% in the fourth quarter. Invesco Ltd. now owns 1,060,263 shares of the company's stock worth $82,796,000 after buying an additional 24,392 shares during the period. Finally, Congress Asset Management Co. raised its holdings in Prestige Consumer Healthcare by 5.0% during the 4th quarter. Congress Asset Management Co. now owns 908,742 shares of the company's stock valued at $70,964,000 after buying an additional 43,619 shares during the last quarter. 99.95% of the stock is currently owned by institutional investors.
Prestige Consumer Healthcare Company Profile
(
Get Free Report)
Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.
See Also
Before you consider Prestige Consumer Healthcare, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prestige Consumer Healthcare wasn't on the list.
While Prestige Consumer Healthcare currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
